CPhI Japan is the country’s most comprehensive pharma event and has been the central platform for international businesses for more than 10 years. Gerald Yakatan, Ph.D., Chairman, CEO and founder of IriSys, will be attending and holding meetings at CPhI Japan in Tokyo on April 19-21, 2017. “CPhI Japan is an excellent setting to discuss IriSys’ customized services that support the special needs of our international clients,” said Gerald Yakatan, Ph.D., Chairman, CEO and founder of the Company. “IriSys has helped numerous foreign companies take their new drug products through the entire FDA regulatory process. In addition to working with Japanese companies, we have helped clients in Australia, China, Korea and Russia.” IriSys helps international companies by providing strategy and guidance throughout the U.S. FDA approval process. In addition, IriSys can educate their clients’ personnel about FDA regulatory requirements and provide translations of regulatory documents. Meetings take place at the client’s location or in San Diego, California, where IriSys maintains its headquarters, laboratories and state-of-the-art manufacturing facility. As Asia’s leading pharma industry and one of the world’s largest markets, Japan is an excellent location to discuss the latest technologies and innovative products. Changes in the market environment, together with an aging population, result in a great drug demand within Japan, especially in the generic and biotechnology sectors. According to the CPhI Japan organizers, the Japanese market is expected to be valued at US $115 billion in 2024. CPhI Japan 2017, which is focused on pharmaceutical ingredients, is expected to have more than 19,000 attendees. Decision-makers representing leading companies from all over the world will participate in a wide range of seminars that include speakers from the government, industry associations and other key organizations.